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Background Skeletal muscle weakness in chronic
obstructive pulmonary disease (COPD) carries a poor
prognosis, therefore a non-invasive marker of this
process could be useful. Reduced expression of muscle-
speciﬁc microRNA (myomiRs) in quadriceps muscle in
patients with COPD is associated with skeletal muscle
weakness and changes in muscle ﬁbre composition.
Circulating exosomal miRNAs can be measured in blood,
making them candidate biomarkers of biopsy phenotype.
To determine whether plasma myomiR levels were
associated with ﬁbre size or ﬁbre proportion, we
measured myomiRs in plasma from patients with COPD
and healthy controls.
Methods and results 103 patients with COPD and
25 age-matched controls were studied. Muscle-speciﬁc
miRNA was elevated in the plasma of patients with
COPD and showed distinct patterns. Speciﬁcally, miR-1
was inversely associated with fat-free mass in the cohort,
whereas levels of miR-499 were more directly associated
with strength and quadriceps type I ﬁbre proportion.
Two miRs not restricted to muscle in origin (miR-16 and
miR-122) did not differ between patients and controls.
Plasma miR-499 was also associated with muscle
nuclear factor κB p50 but not p65 in patients with early
COPD whereas plasma inﬂammatory cytokines were
associated with miR-206 in patients with more advanced
disease.
Conclusions Plasma levels of individual myomiRs are
altered in patients with COPD but alone do not predict
muscle ﬁbre size or proportion. Our ﬁndings are
consistent with an increase in muscle wasting and
turnover associated with the development of skeletal
muscle dysfunction and ﬁbre-type shift in patients with
stable COPD.
INTRODUCTION
Patients with chronic obstructive pulmonary disease
(COPD) can demonstrate weakness due to reduced
muscle mass and ﬁbre size1 2 and reduced muscle
endurance due to a shift to reduced type I muscle
ﬁbre proportions.3 4 Quadriceps weakness5 6 and
wasting7 are present in spirometrically mild disease,
but are predictors of mortality among patients with
moderate to severe COPD, independent of lung
function.8 The ﬁbre-type shift towards a predomin-
ance of fast ﬁbres (mainly type IIa)4 9 10 is inde-
pendently associated with exercise intolerance in
COPD.3 11 12
The available data suggest considerable hetero-
geneity in the lower limb muscle ﬁbre size and
proportions in patients with COPD.3 13 Potential
therapeutic agents might address different facets of
skeletal muscle dysfunction in COPD; in particular
a drug which improved muscle bulk might not
reverse ﬁbre shift and vice versa, making biomar-
kers of skeletal muscle composition useful.14
The control of muscle mass and composition is
complex, involving numerous transcription factors
and other regulators including microRNAs. In
muscle, much attention has focussed on miR-1,
miR-499, miR-206, miR-133 (myomiRs) and
miR-181. Some myomiRs affect myocyte prolifer-
ation and differentiation, and are organised as
bicistronic genes, for example the miR-1 family.15
Others, for example miR-208b and miR-499,1516
are encoded within the slow myosin heavy chain
(MHC) genes17 and thereby are restricted to type I
ﬁbres where they modulate ﬁbre type.17 18 Mir-181
is thought to maintain muscle mass in an activity-
dependent manner. We have previously shown that
expression of miR-1 and miR-499 is suppressed in
the quadriceps of patients with COPD.19
MiRNAs circulate in blood and are resistant to
endogenous RNAses,20 therefore circulating
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miRNAs are potential disease biomarkers.21 We predicted that
plasma levels of myomiRs differ between patients with COPD
and age-matched healthy controls and are associated with ﬁbre
cross-sectional area (CSA) and ﬁbre type proportions in patients.
Furthermore, we investigated associations of plasma myomiRs
with inﬂammatory signalling to provide insight into potential
mechanisms of muscle wasting in COPD.
METHODS
Subjects
Patients with COPD according to the Global Initiative for
Obstructive Lung Disease guidelines 200422 (36 women, 67
men) were enrolled from clinics at the Royal Brompton
Hospital (GOLD I or II, n=34; III, n=38; IV, n=31). Patient
exclusion criteria and ethical approval are described in the
online supplement. Control subjects (n=25) were recruited by
local advertisement. Data on lung function, strength, ﬁbre size,
ﬁbre proportion and MHC expression from this cohort have
been published previously.19 23 24
Physiological measurements
Measurements of lung volume, carbon monoxide transfer,
blood gases, fat-free mass index (FFMI), quadriceps strength
(maximum voluntary contraction (MVC)), and exercise per-
formance (6 min walk distance (6MWD)) are described in the
online supplement.
Quadriceps muscle biopsy assessment
Percutaneous needle biopsy of the vastus lateralis in the anterior
mid-thigh of the leg on which strength was tested was per-
formed under local anaesthesia using the Bergstrom
technique.25 Fibre size and ﬁbre proportion were determined by
immunoﬂuorescence. Messenger RNA (mRNA) was extracted
and quantiﬁed as described previously26 and in the online sup-
plement. Quadriceps nuclear factor κB (NFκB) p50 and p65
subunits were analysed using transcription factor ELISA, also
detailed in the online supplement.
Measurement of circulating miRNA and cytokine levels
Stored plasma samples were denatured, spiked with a synthetic
RNA for normalisation,27 poly-adenylated and reverse tran-
scribed and each miRNA was quantiﬁed by quantitative real-
time PCR. Detailed methods are given in the online supplement.
Cytokine levels were determined by luminex as described in the
online supplement.
Data analysis
Data were analysed by Student’s t test, ANOVA, Man–Whitney
U test, Pearson correlation and receiver operating characteristic
(ROC) analysis as appropriate and as described in the online
supplement.
RESULTS
Patient characteristics and muscle phenotype
Consistent with a diagnosis of COPD, the patients had impaired
lung function (forced expiratory volume in 1 s (FEV1) and gas
transfer) and reduced arterial blood oxygen tensions compared
with controls. There was no difference in age, body mass index,
FFMI or arterial blood CO2 tensions between groups. Patients
had a signiﬁcantly reduced quadriceps force (MVC and twitch
force) and exercise capacity measured by 6MWD compared
with controls (table 1). Patients with GOLD III and GOLD IV
Table 1 Clinical characteristics of study subjects
Condition Control COPD Significance of difference, p value
Number 25 103
M (F) 14 (11) 67 (36) 0.4888 (F)
Age 67.04 (8.1) 66.47 (8.4) 0.757 (T)
Height (cm) 168 (8.9) 168 (8.6) 0.886 (T)
Weight (kg)* 69.1 (83.5, 62) 68.8 (80.6, 59.5) 0.359 (MW)
BMI (kg/m2)* 24.8 (27.05, 24) 24.1 (27, 21.4) 0.134 (MW)
FFMI (kg/m2)* 16.4 (19.8, 15.2) 15.7 (17.2, 14.5) 0.060 (MW)
Pack year smoking* 0 (8.75, 0) 45 (60.6, 34) <0.001 (MW)
FEV1 (% pred)* 110 (114, 101) 42 (57, 27) <0.001 (MW)
RV/TLC (%) 37 (4.8) 57 (9.2) <0.001 (T)
TLCO (% pred) 91 (14.2) 43 (17.6) <0.001 (T)
PaCO2 (kPa) 5.28 (0.4) 5.14 (0.6) 0.337 (T)
PaO2 (kPa) 11.0 (1.2) 9.31 (1.3) <0.001 (T)
6MWD (m) 614 (83) 394 (120). <0.001 (T)
SGRQ* 2 (7.5, 0) 54 (64, 43) <0.001 (MW)
Best MVC (kg) 35.8 (10.2) 29.5 (10.2) 0.006 (T)
Best TwQ (kg)* 8.6 (11.4, 7.0) 7.6 (9.2, 6) 0.081 (MW)
MVC/wt (kg/kg)* 0.49 (0.38, 0.57) 0.41 (0.37, 0.51) 0.014 (MW)
MHCI mRNA (AU)* 32 (48, 20) 7.3 (14.5, 4.6) <0.001 (MW)
MHCIIa mRNA (AU)* 1.6 (2.3, 0.9) 2.5 (3.8, 1.5) 0.045 (MW)
MHCIIx mRNA (AU)* 5.2 (8.1, 4.2) 11.4 (19.3,8.0) <0.001 (MW)
Values are mean (SD) for normally distributed data or median (75th, 25th percentile) for non-normally distributed data in patients with COPD or healthy controls (indicated by*).
p Values were calculated by t test (normally distributed data, T), Mann–Whitney test (non-normally distributed data, MW) or Fischer’s exact test (F) and are shown in bold when
p<0.05. MHC RNAs were determined by quantitative PCR and normalised to the expression of RPLPO in the same samples as described in the online supplement.
6MWD, 6 min walk distance; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CSA, cross-sectional area; FEV1, forced expiratory volume in 1 s; FFMI, fat-free mass
index; MHC, myosin heavy chain; MVC, maximal voluntary contraction; PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; pred, predicted; RV, residual volume;
SGRQ, St George’s Respiratory Questionnaire; TLC, total lung capacity; TLCO, transfer factor of the lung for carbon monoxide; TwQ, twitch force in the quadriceps.
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COPD had signiﬁcantly lower FFMI than those with GOLD II
COPD and patients with GOLD IV COPD had signiﬁcantly
worse 6MWD compared with those with GOLD II or III.
Quadriceps strength did not differ signiﬁcantly across the
GOLD stages (see online supplementary table S1, ﬁgure S1).
Quadriceps muscle ﬁbre size and proportion for the entire
cohort have been reported.3 The association of ﬁbre type and
size with GOLD stage for those included in this study is shown
in online supplementary table S1. From that report we highlight
that the patients had markedly smaller IIX ﬁbres (p<0.001),
more type II ﬁbres and fewer type I ﬁbres. Neither ﬁbre propor-
tion nor ﬁbre CSA was different between the GOLD groups (see
online supplementary table S1).
MiRNA levels in the plasma of patients with COPD
compared with control subjects
Circulating levels of miR-1, miR-499, miR-206 and miR-133 were
signiﬁcantly elevated in the plasma of patients with COPD com-
pared with those in controls (ﬁgure 1). MiR-1 and miR-499 had
the greatest fold difference, 2.5 and 1.5 times higher in patients
with COPD and controls respectively. The trend towards an
increase in miR-181 did not reach signiﬁcance (p=0.052). By con-
trast there was no difference in levels of miR-16 (an miRNA previ-
ously used as a control in plasma27) or miR-122 (a liver-speciﬁc
miRNA28), both serving as non-muscle-speciﬁc miR controls (see
online supplementary ﬁgure S2) or in the spiked in exogenous
control raw cycle threshold values in patients compared with
controls (p=0.308). As smoking affects miRNA levels in the lung
we compared plasma levels of the miRNAs in current (n=16) and
ex-smokers (n=87) with COPD; smoking status did not affect
plasma miRNA levels signiﬁcantly.
Plasma microRNA and lung function
MiR-1 was negatively but modestly associated with FEV1 as %
predicted (r=−0.3, p=0.001) and with the transfer factor of the
lung for carbon monoxide (TLco)% predicted (r=−0.3,
p=0.002) when all subjects were analysed (ﬁgure 2). MiR-499,
miR-206 and miR-133 showed a distinct and similar pattern.
Although plasma miRNA was higher in patients than in the con-
trols, within the patient group, the miRNAs were higher in
patients with the most preserved lung function (ﬁgure 2; see
also online supplementary ﬁgure S3). Patients with GOLD IV
COPD had lower plasma miR-499 and miR-206 than those
with GOLD II COPD (p=0.004 and p=0.007 respectively; see
online supplementary ﬁgure S3) and both miRNAs had a
modest positive correlation with FEV1% predicted within the
patients alone (miR-499 r=0.26, p=0.007; miR-206 r=0.25,
p=0.013; ﬁgure 2). Neither miR-16 nor miR-122 varied with
GOLD stage (see online supplementary ﬁgure S4). Although
there were no overt differences in miRNA levels between
smokers and ex-smokers with COPD, because of the potential
confounder of smoking status, we re-analysed these correlations
in ex-smoking patients alone and found that the correlation was
Figure 1 Muscle-derived miRNAs are elevated in the plasma of patients with stable chronic obstructive pulmonary disease (COPD). Plasma miR
levels were measured as described in ‘Methods’ and normalised to a spiked Caenorhabditis elegans control. Data are presented as log-normalised
levels with the notched boxes showing median and IQR, error bars at the 10th and 90th percentile, outliers are also shown. Patients with Global
Initiative for Obstructive Lung Disease (GOLD) stage I and II COPD are represented by ﬁlled grey circles, those with GOLD stage III and IV disease are
represented by ﬁlled black circles and controls are shown as open grey circles. Statistical signiﬁcance was calculated by t test or Mann–Whitney U
test as the non-parametric alternative.
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numerically strengthened despite a smaller number of data
points (miR-499 r=0.3, p=0.006; miR-206, r=0.34 p=0.001).
Plasma microRNA, muscle mass and strength
Plasma miR-1 levels negatively correlated with FFMI when patients
were analysed either with or without the controls (r=−0.21,
p=0.036 and r=–0.25, p=0.013, respectively; ﬁgure 3) and also
correlated with type I ﬁbre CSA in patients (r=−0.27, p=0.027;
ﬁgure 3). In ex-smoking patients FFMI was more strongly asso-
ciated with plasma miR-1 than in the entire patient cohort
(r=−0.30, p=0.005; see online supplementary ﬁgure S5).
However, there was no association of miR-1 with strength.
The other myomiRs were not associated with FFMI or with
ﬁbre CSA and showed only weak correlations between circulat-
ing miR levels and measures of quadriceps strength. MiR-133,
miR-499 and miR-206 weakly correlated with quadriceps MVC
corrected for weight (r=0.23, p=0.022; r=0.20, p=0.036; and
r=0.21, p=0.034, respectively). In ex-smoking patients the
associations were stronger than in the whole cohort (r=0.29,
p=0.008; r=0.27, p=0.013; and r=0.28, p=0.009; see online
supplementary ﬁgure S5).
Plasma miRNAs and ﬁbre shift
Reduced lung function indices are associated with a reduction in
the percentage of type I ﬁbres (TI%). In the entire patient group
none of the miRNAs were associated with TI%. However,
restricting the patient group to those with GOLD III and IV
disease showed a weak association between plasma miR-499
and TI% (r=0.26, p=0.033) and plasma miR-499 was signiﬁ-
cantly lower in those with evidence of pathological ﬁbre shift
(ﬁgure 4). MiR-499 was positively correlated with 6MWD
(r=0.22, p=0.028; ﬁgure 4), an association numerically
strengthened by considering ex-smoking patients alone (r=0.25,
p=0.020). However, miR-499 was not correlated with quadri-
ceps endurance.
To determine whether plasma myomiRs are useful predictors of
ﬁbre-type shift, we performed ROC analysis which showed that
TLCO% predicted and 6MWD% predicted were better predictors
of ﬁbre shift than the plasma miRNAs alone in patients with
GOLD III and IV COPD, but combining these values, the ROC
area under the curve (AUC) increased to 0.89 (table 2, ﬁgure 5 and
see online supplementary ﬁgure S6). Inclusion of patients with
GOLD I and II COPD (who did not show an association between
Figure 2 Association of plasma miRNAs with lung function. Plasma miRNAs were determined as described in ‘Methods’ and compared with
forced expiratory volume in 1 s (FEV1) % predicted. MiR-1 showed a negative association with FEV1 across the whole cohort (A) whereas miR-499
(B) and miR-206 (C) were highest in patients with early stage chronic obstructive pulmonary disease (COPD) (Global Initiative for Obstructive Lung
Disease (GOLD) I and II). Consequently although miR-499 and miR-206 levels were signiﬁcantly higher in patients than controls (see ﬁgure 1) there
was a negative association of these miRNAs with FEV1 within the patients group alone (miR-499 r=0.29, p<0.003; miR-206 r=0.26, p<0.009).
Patients with GOLD I and II COPD are represented by ﬁlled grey circles, those with GOLD III and IV COPD are represented by ﬁlled black circles and
control subjects are represented by open grey circles.
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TI% and plasma miR-499) reduced the predictive value of physio-
logical and miRNA values for ﬁbre shift (eg, TLCO% predicted
AUC=0.70 and the combined score AUC=0.79).
Plasma miR-499 with markers of inﬂammation
To investigate potential mechanisms contributing to the increase
in plasma myomiRs we compared NFκB p50 and NFκB p60 in
nuclei prepared from quadriceps muscle with plasma myomiR
levels. Overall, there was no difference in NFκB p65 and p50
binding DNA in patients compared with controls (p=0.134 and
p=0.968, respectively; see online supplementary table S1), and
there was no relationship of these factors with muscle mass, ﬁbre
type or function. However, miR-499 levels were found to correl-
ate weakly with nuclear NFκB p50 (r=0.198, p=0.028). This
association persisted when only patients with COPD were con-
sidered (r=0.23, p=0.021). Restricting the patients to GOLD I
and II only strengthened the association of nuclear NFκB p50
with miR-499 (r=0.58, p<0.001), while an association was
absent in patients with GOLD III and IV COPD (r=0.142,
p=0.255; ﬁgure 6). While miR-1 did not correlate with nuclear
NF-κB p50 in any group, miR-133 (r=0.47, p=0.006) and
miR-206 (r=0.4, p=0.016) were associated with nuclear NFκB
p50 in patients with GOLD I and II COPD. There were no asso-
ciations of plasma miRNAs with nuclear NFκB p65.
Plasma myomiR levels were also compared with circulating
levels of tumour necrosis factor α, interleukin 2 (IL2) and IL5.
In the patients alone, plasma levels of miR-206, miR-133 and
miR-499, but not miR-1, were associated with plasma levels of
the cytokines (ﬁgure 7, table 3), in particular in patients with
GOLD III and IV disease. The strongest associations between
the circulating cytokines and myomiRs were with miR-206 and
the weakest associations were with miR-499 (ﬁgure 7).
DISCUSSION
The main ﬁnding of this study is that, in patients with stable
COPD, plasma levels of muscle-speciﬁc miRNAs but not of two
control miRNAs are increased, suggesting that muscle wasting
or turnover is increased even in those with stable COPD.
Furthermore, we show that different miRNAs have distinct
plasma proﬁles dependent on disease severity and on the pro-
portion of oxidative ﬁbres remaining in the quadriceps. Alone
these miRNAs show weak discrimination of patients with type I
ﬁbre shift, but they improve the utility of TLCO% predicted and
6MWD% predicted to identify patients with pathological type I
ﬁbre shift in those with GOLD III and IV disease. Finally we
show that in mild/moderate disease, plasma levels of miR-499
are associated with nuclear NFκB p50 but not NFκB p65,
whereas in severe/very severe disease, miR-206 and miR-133 are
associated with circulating cytokines. These data raise the possi-
bility that wasting in mild disease is predominantly driven by
inactivity but in severe disease is associated with systemic
inﬂammation.
Signiﬁcance of the ﬁndings
The purpose of this study was to identify biomarkers and
mechanisms of skeletal muscle dysfunction and ﬁbre abnormal-
ities in COPD.
Disease process and mechanism
Increased plasma myomiRs are associated with wasting in
animals and humans. For example, in patients with Duchenne
muscular dystrophy and in mdx mice serum levels of miR-1,
miR-133 and miR-206 are elevated,29 suggesting that the
increase in plasma myomiRs observed in our cohort derives
from atrophying muscle or muscle with elevated turnover. As
our patients were in the stable phase of COPD, these data indi-
cate that increased muscle turnover occurs in patients with
COPD in the absence of current or recent exacerbation.
Although plasma levels of miR-499, miR-133 and miR-206
were elevated in patients compared with controls, within the
patient group the highest plasma levels were associated with
better lung function. This apparent paradox could be explained
Figure 3 Plasma miR-1 is weakly associated with fat-free mass and type I ﬁbre cross-sectional area (CSA) in patients with chronic obstructive
pulmonary disease (COPD). Physiological parameters and plasma miRNA levels were determined as described in ‘Methods’. (A) Plasma miR-1 levels
negatively correlated with fat-free mass index when patients with COPD were analysed either with or without the controls (as shown in the ﬁgure),
r=−0.21, p=0.036 and r=−0.25, p=0.013, respectively. (B) Plasma miR-1 levels were negatively correlated with type I ﬁbre CSA in patients
(r=–0.27, p=0.027). Patients with Global Initiative for Obstructive Lung Disease (GOLD) I and II COPD are represented by ﬁlled grey circles, those
with GOLD III and IV COPD are represented by ﬁlled black circles.
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Figure 4 Association of plasma miR-499 and ﬁbre proportion in patients with Global Initiative for Obstructive Lung Disease (GOLD) III and IV
chronic obstructive pulmonary disease (COPD). Plasma miR-499 was determined as described in ‘Methods’. In the entire patient group none of the
miRNAs were associated with the percentage of type I ﬁbre (TI%) in quadriceps muscle biopsy. (A) Comparison of ﬁbre proportion and plasma
miR-499 levels in patients with GOLD III and IV COPD showed a weak association of plasma miR-499 with TI% in quadriceps biopsies (r=0.26,
p=0.033). (B) In the entire patient cohort, comparison of plasma miR-499 in patients with ﬁbre shift (deﬁned as a TI% below the 2.5th percentile
for the control cohort) with those without ﬁbre shift had higher plasma miR-499. Median (25th, 75th percentile) log AU=4.113 (3.781, 4.412) and
3.898 (3.594, 4.126) respectively (Mann–Whitney test). Error bars are 10th percentile and 90th percentile and outliers are shown. (C) Comparison of
6 min walk distance with plasma miR-499 showed a weak association in the entire patient cohort (r=0.22, p=0.028). Patients with GOLD I and II
COPD are represented by ﬁlled grey circles and those with GOLD III and IV COPD are represented by black circles.
Table 2 ROC analysis multiplied by −1, predicting presence of type I fibre shift











+ + + 0.86
+ + + + 0.87
+ + + + + + 0.89
Components included in each ROC analysis are indicated by +.
6MWD, 6 min walk distance; AUC, area under the curve; pred, predicted; ROC, receiver operating characteristic; TLCO, transfer factor of the lung for carbon monoxide.
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by differences in the muscle pool in patients with mild versus
severe disease. Patients with severe disease have a lower muscle
mass from which to release miRNA compared with patients
with mild disease. Also, patients with more severe disease have a
lower proportion of type I ﬁbres from which to release
miR-499 compared with patients with mild disease, miR-499
being encoded within a slow MHC gene and so only expressed
in type I ﬁbres.17 The decrease in miR-499 observed in patients
with severe lung function impairment is consistent with observa-
tions from patients with lung cancer in whom low plasma levels
of miR-499 were a predictor of reduced survival,30 perhaps as a
result of cachexia.
Our data also show that in mild COPD, plasma miR-499 levels
are directly correlated with nuclear NFκB p50. This observation
allows us to tentatively speculate that loss of type I ﬁbres or export
of miR-499 is dependent on NFκB activation. However, as plasma
miR-499 levels were not associated with NFκB p65, the data
suggest that the increase in plasma miR-499 is associated with the
non-canonical NFκB pathway that utilises NFκB p50 and BCl3 in
response to physical inactivity as demonstrated by transgenic
mouse models.31 Alternatively, since miRs can be exported in an
active and selective manner,32 it is possible that NFκB p50 drives
the export of miR-499 from type I ﬁbres. Given the role of
miR-499 in type I ﬁbre maintenance, directed secretion of
miR-499 may be required for ﬁbre switching in response to
inactivity. Again this process would be most active in the earlier
stages of the disease when there are more type I ﬁbres. Plasma
cytokines were also associated with plasma myomiRs, in particular
miR-206 and miR-133 in patients with severe disease. This obser-
vation raises the possibility that inﬂammation is an important
driver of wasting in this patient subgroup. Alternatively, as there
was no association of the plasma myomiRs and nuclear NFκB
p65, the plasma myomiRs and inﬂammatory cytokines could be
associated in a NFκB-independent manner.
Plasma myomiRs as diagnostic tools in COPD-associated
ﬁbre-type abnormalities
Muscle biopsy is the only way to investigate ﬁbre-type changes
but is invasive, introducing discomfort and inconvenience to the
patient. Therefore, it would be very useful to identify a less
Figure 5 Receiver operating characteristic (ROC) analyses of physiological parameters alone or in combination with plasma miRNA levels to
discriminate patients according to the presence of type I ﬁbre shift. Patients with Global Initiative for Obstructive Lung Disease (GOLD) III and IV
disease were deﬁned as having type I ﬁbre shift or not as described in ‘Results’. ROC analysis was then performed as described in ‘Methods’ using
transfer factor of the lung for carbon monoxide (TLCO) expressed as % predicted (A), 6 min walk distance (6MWD) as % predicted (B), combination
score (generated by combining TLCO % predicted, 6MWD % predicted, plasma miR-1 level, plasma miR-499 level, plasma miR-181 level and plasma
miR-206 level, as described in ‘Methods’) (C). Area under the curve (AUC) is shown in each graph. (D) Comparison of the combined score in
patients with or without ﬁbre shift. Patients with GOLD III and IV disease with ﬁbre shift have a signiﬁcantly different score (p<0.001) than patients
of the same disease severity without ﬁbre shift. TPF, true positive fraction.
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invasive measure of muscle ﬁbre-type abnormalities. Alone,
neither the miRNAs studied here nor the physiological para-
meters are sufﬁcient to identify patients with a signiﬁcant ﬁbre
shift. However, by combining these factors we were able to
improve discrimination for identifying type I ﬁbre shift. This
approach only worked in the severe disease groups (GOLD III
and IV), presumably because the more dynamic changes in quad-
riceps mass have already occurred.7 Whilst not sufﬁcient to
replace muscle biopsy based on the present data, increasing the
number of miRNAs proﬁled has potential to improve the predict-
ive power further, while a larger study would increase the power
to detect a potential biomarker from the targets already studied.
Critique of the method
The myomiRs we evaluated are known to be highly enriched in
muscle, suggesting that the majority of myomiRs measured in
plasma are of muscle origin. However, with the exception of
miR-206 these miRNAs could come from either cardiac or skel-
etal muscle; miR-206 is almost exclusively expressed in skeletal
muscle and is not readily detectable in the heart by RNAse
protection33 or real-time PCR.34 Given that miR-133 and
miR-499 show very similar patterns in patients with COPD to
that of miR-206, they are also likely to be of skeletal muscle
origin. MiR-1 plasma levels had a linear correlation with FEV1,
unlike the other myomiRs and miR-1 was present at the lowest
levels. Cardiac muscle is another potential source of miR-1,
miR-133 and miR-499, but studies have failed to demonstrate
major changes in circulating myomiRs in chronic heart failure,
diastolic dysfunction or hypertrophy,35 suggesting that the heart
is an unlikely contributor to the elevation of plasma myomiRs
in patients with COPD. It is not possible to determine the pro-
portion of each myomiR that is derived from individual
muscles. However, the quadriceps muscle contributes approxi-
mately 40% of the skeletal muscle bulk and is known to be the
predominant muscle affected in patients with COPD, even
within the lower limb.36 If the diaphragm was the major source
of the elevated plasma myomiRs, we would have predicted an
increase in miR-499 as a result of the increase in TI% in the dia-
phragm in patients with COPD compared with controls, and
potentially an increase in miR-499 with advancing GOLD
Figure 6 Plasma miR-499, miR-133 and miR-206 are correlated with the amount of nuclear factor κB (NFκB) in the quadriceps nuclei of patients
with Global Initiative for Obstructive Lung Disease (GOLD) I and II chronic obstructive pulmonary disease (COPD). Log normalised plasma miR-499
(determined as described in ‘Methods’) was compared with NFκB p50 determined by transcription factor ELISA. In patients with GOLD I and II
COPD there was a direct association between NFκB p50 (r=0.58, p<0.001) and miR-499 (A) that was not present when analysing patients with
GOLD III and IV COPD (r=0.142, p=0.25 (B). In patients with GOLD I and II COPD NFκB p50 was also correlated with miR-206 (r=0.4 p=0.016 (C)
and miR-133 (r=0.47, p=0.006 (D). Patients with GOLD I and II COPD are represented by ﬁlled grey circles, those with GOLD III and IV COPD are
represented by ﬁlled black circles.
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stage,37 neither of which were seen. It is therefore likely that
quadriceps muscle is the main contributor to changes in plasma
myomiRs.
This study is a cross sectional analysis of a large cohort of
patients with COPD with plasma myomiRs measured at a single
time point and as such we can only speculate on changes that
Figure 7 Plasma miR-499 and miR-206 are associated with plasma interleukin 2 (IL-2) in patients with chronic obstructive pulmonary disease
(COPD). Log normalised plasma miR levels (determined as described in ‘Methods’) were compared with plasma IL-2 levels determined by ELISA.
miR-206 was not associated with plasma IL-2 in patients with Global Initiative for Obstructive Lung Disease (GOLD) I and II COPD but was positively
associated with plasma IL-2 in GOLD III and IV COPD (B) (r=0.39, p<0.001). miR-499 was not associated with IL-2 in patients with GOLD I and II
COPD (C) or in patients with GOLD III and IV COPD (D). Patients with GOLD I and II COPD are represented by ﬁlled grey circles and those with
GOLD III and IV COPD are represented by ﬁlled black circles.
Table 3 Pearson correlation coefficients for the association of plasma myomiRs with plasma cytokines
Cytokine
miR-499 miR-133 Mir-206
Patient group r p r p r p
IL-2 0.33 0.056 0.35 0.049 0.32 0.07
GOLD I/II IL-5 0.22 0.202 0.23 0.201 0.42 0.016
TNF 0.25 0.162 0.28 0.118 0.36 0.038
IL-2 0.15 0.223 0.37 0.002 0.39 <0.001
GOLD III/IV IL-5 0.238 0.052 0.39 <0.001 0.38 <0.001
TNF 0.27 0.023 0.25 0.042 0.36 0.038
IL-2 0.33 <0.001 0.34 <0.001 0.36 <0.001
All IL-5 0.31 0.002 0.32 <0.001 0.34 <0.001
TNF 0.22 0.026 0.22 0.025 0.27 0.007
GOLD, Global Initiative for Obstructive Lung Disease; IL, interleukin; TNF, tumour necrosis factor.
Bold signifies statistically significant correlation p<0.01.
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might occur over time. Our data are therefore correlative in
nature and the associations do not show causation.
CONCLUSIONS
This study demonstrates elevated muscle-speciﬁc miRNAs in the
plasma of patients with COPD compared with controls. Our ﬁnd-
ings are consistent with an increase in muscle wasting and turnover,
associated with the development of skeletal muscle dysfunction
and ﬁbre-type shift in patients with COPD. Despite the complex
pathophysiology underlying circulating myomiRs, the, albeit weak,
correlations of plasma myomiRs with quadriceps function and ﬁbre
characteristics suggest that the quadriceps are a signiﬁcant contribu-
tor to the changes in plasma myomiRs in COPD. We do not offer a
biological function for the circulating miRs, but suggest that the
amount reﬂects the underlying skeletal muscle mass, rate of turn-
over and muscle ﬁbre-type composition of patients.
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